In patients with clear cell renal cell carcinoma (ccRCC), there are a number of second-line options to consider. Sumanta K.

A higher dose of anti-T-lymphocyte globulin (ATLG) significantly outperformed a lower dose in preventing graft-vs-host ...

The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1 +, a DNA plasmid vaccine, in patients with advanced melanoma, scheduled to commence ...

In an interview with Targeted Oncology, lead author Brian M. Slomovitz, MD, discusses this move toward a "breast cancer model ...

SEQTOR trial shows comparable PFS for STZ/5-FU followed by everolimus and the reverse sequence in advanced pancreatic NETs. STZ/5-FU demonstrated higher response rates, beneficial for rapid tumor ...

In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

G-CSF Limitations: These agents essentially overstimulate a bone marrow that is already damaged by chemotherapy. Furthermore, ...

The FDA has granted priority review to the new drug application (NDA) for gedatolisib, a first-in-class multi-target ...

During a live event, Andrew H. Lipsky, MD, and participants discuss emerging trial data and real-world applications of ...

Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...

This episode of Treating Together, hosted by Chandler Park, MD, featuring guests Benjamin Garmezy, MD, and Manoj Bupathi, MD, ...